Search the Newsreel

Immunovant's $797.8M Cash Provides Runway to Potential Drug Launch

Immunovant (IMVT) reported its fiscal first-quarter 2026 financial results, including a net loss of $153.2 million and R&D expenses of $142.6 million. Despite increased R&D, the company's cash and cash equivalents of $797.8 million as of June 30, 2026, are projected to provide sufficient …

Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss

Immunovant (IMVT) reported a fiscal Q1 loss of $0.75 per share, which is wider than the FactSet estimate of a $0.65 loss per share. The company is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. Its pipeline includes product candidates …

ImmuCell Corporation (ICCC) Rises 2.33% to $11.0 as Shares Hold Key Support - Arms Index

Renaissance Technologies LLC Raises Stake in MoonLake Immunotherapeutics $MLTX

ImmuCell (ICCC) Expected to Release Earnings on Thursday

Lyell Immunopharma (LYEL) Earnings Date and Reports 2026 $LYEL

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – FWB:6YG

Immunocore Holdings Plc (FWB:6YG) generated €340.58 million in revenue last year, primarily from its Immunotherapies segment. The United States was the largest geographical contributor, accounting for €218.81 million of the company's revenue. The article highlights the company's top-performing segment and its major market.

Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy

Stifel initiated coverage on Lyell Immunopharma (NASDAQ:LYEL) with a buy rating and a price target of $36.00, citing the potential of its Rondecabtagene autoleucel (Ronde-cel) CAR T-cell therapy. The firm believes Ronde-cel could achieve clinical superiority and regulatory approvals by 2028 and 2030, projecting …

BTIG Research Reaffirms "Buy" Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU) Announces Earnings Results, Misses Estimates By $0.09 EPS

Immuneering (NASDAQ:IMRX) Releases Earnings Results

Laurion Capital discloses 6.06% Immunic (IMUX) stake via shares and warrants

Laurion Capital Management LP and its related entities have disclosed a 6.06% beneficial ownership stake in Immunic, Inc. (IMUX) as of June 30, 2026. This stake comprises 839,526 shares, including common stock and shares issuable upon the exercise of warrants. The filing indicates shared …

Immunocore set to report earnings ahead of pivotal trial data

Immunocore Holdings PLC is set to report second-quarter financial results with investors focusing on the commercial performance of its drug KIMMTRAK and the progress of its clinical trial for cutaneous melanoma. Analysts anticipate earnings of $0.01 per share on $110.3 million in revenue. The …

Immunocore Q2 2026 Earnings Preview

* Immunocore (IMCR [https://seekingalpha.com/symbol/IMCR]) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. * The consensus EPS Estimate is $0.02 [https://seekingalpha.com/symbol/IMCR/earnings/estimates] (+110.0% Y/Y) and the consensus Revenue Estimate is $110.37M (+12.6% Y/Y). * Over the last 3 months, EPS …

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio IBRX reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period's loss of 10 cents. Total revenues …

Immunocore Holdings PLC Sponsored ADR $IMCR Position Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC increased its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 30.9% in the first quarter, now owning 594,712 shares worth $17.9 million. Several other institutional investors also adjusted their positions, with institutional investors and hedge funds collectively owning 84.5% …

AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026Phase 2 VacSYn trial of ACI-7104 in Parkinson’s …

Altimmune to discuss its liver-treatment candidate Aug. 12

Altimmune (Nasdaq: ALT) will report its second quarter 2026 financial results on Wednesday, August 12, 2026, including a conference call and webcast at 8:30 a.m. ET to review results and provide a business update. The company is a late clinical-stage biopharmaceutical company developing pemvidutide …

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune, Inc. (Nasdaq: ALT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 12, 2026. Management will host a conference call at 8:30 a.m. ET to discuss the results and update, which will also be …

AC Immune: Q2 Earnings Snapshot

AC Immune’s Parkinson’s Trial Gets a $4 Million Grant

AC Immune (NASDAQ: ACIU) reported its first-half 2026 financial and corporate update, highlighting a $4 million grant for its Phase 2 VacSYn trial (ACI-7104) for Parkinson’s disease. The company also received a $12 million milestone payment from Takeda for initiating a new cohort in …

Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA

The article focuses on the "Price to book forward" metric for Estrella Immunopharma, Inc. (NASDAQ: ESLA), a health technology and biotechnology company. It presents a snapshot of the company's financial overview within the TradingView platform, noting that the market was closed at the time …

Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss

Estrella Immunopharma (ESLA) Rallies 6.11% as CAR T-Cell Focus Draws Investor Attention - Earnings Sentiment

Immuneering (NASDAQ: IMRX) posts Q2 loss while funding MAPKeeper 301 into 2029

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW

Pomerantz LLP has filed a class action lawsuit against Immunovant, Inc. (formerly Health Sciences Acquisitions Corporation) and some of its officers, seeking to recover damages for investors who purchased Immunovant securities between October 2, 2019, and February 1, 2021. The lawsuit alleges that Immunovant …

IMUX Technical Analysis & ETF Price Forecast

The article provides a technical analysis of Immunic, Inc. (IMUX), indicating a "Neutral" sentiment based on various technical indicators. While some moving averages suggest a "Buy" signal given the current share price of $14.05, momentum indicators like RSI and MACD are currently neutral. The …

Edgestream Partners L.P. Makes New $1.31 Million Investment in Immunome, Inc. $IMNM

Edgestream Partners L.P. has made a new $1.31 million investment in Immunome, Inc. (NASDAQ:IMNM), acquiring 59,888 shares. This investment highlights continued institutional interest, with other hedge funds also adjusting their positions, bringing total institutional ownership to 44.58%. Despite analyst recommendations for a "Moderate Buy" …

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) reported a Q2 loss of $0.08 per share, surpassing the Zacks Consensus Estimate of a $0.09 loss and showing an 11.11% earnings surprise. The company also beat revenue estimates, posting $51.24 million against an estimated $48.45 million. ImmunityBio's stock has seen a …

Insider at IMNM (NASDAQ: IMNM) plans sale of 90,616 shares

Alfred K. Horn, an insider at Immunome Inc. (NASDAQ: IMNM), has filed a Form 144 notice to sell up to 90,616 shares of common stock on August 4, 2026, through Fidelity Brokerage Services LLC. This planned sale is in connection with a stock option …

Perceptive Advisors LLC Lowers Stake in Immunovant, Inc. $IMVT

Perceptive Advisors LLC reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 19.9% in the first quarter of 2026, selling 397,507 shares but still retaining 1.60 million shares valued at approximately $39.7 million. Despite this, institutional investors collectively own 47.08% of the company. Immunovant shares …

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday

Lyell Immunopharma (NASDAQ:LYEL) is expected to announce its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $2.0243 per share and $5,000 in revenue. Despite a consensus "Moderate Buy" rating and a target price of $43.20, the …

Immunitybio Inc earnings missed by $0.14, revenue topped estimates

Immunitybio Inc (NASDAQ: IBRX) reported second-quarter EPS of $-0.22, missing analyst estimates by $0.14. However, the company's revenue of $51.24M surpassed the consensus estimate of $47.22M. The stock has seen a significant increase of 196.68% over the last 12 months, despite a recent 7.86% …

ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings

IMVT Maintained by JP Morgan -- Price Target Raised to $50.00

JP Morgan has maintained an Overweight rating on Immunovant (IMVT), increasing its price target to $50.00 from $47.00. Despite this positive analyst outlook, Immunovant holds a low GF Score™ of 29/100, indicating challenges in profitability and growth, and has seen significant insider selling. The …